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Measurement of exhaled nitric oxide is widely used in respiratory research and clinical
practice, especially in patients with asthma. However, interpretation is often difﬁcult, due
to common interfering factors, and little is known about interactions between factors. We
assessed the inﬂuences and interactions of factors such as smoking, respiratory tract
infections and respiratory allergy concerning exhaled nitric oxide values, with the aim to
derive a scheme for adjustment. We studied 897 subjects (514 females, 383 males; mean
age7standard deviation 34.5713.0 years) with and without respiratory allergy (allergic
rhinitis and/or asthma), smoking and respiratory tract infection. Logarithmic nitric oxide
levels were described by an additive model comprising respiratory allergy, smoking,
respiratory tract infection, gender and height (pp0.001 each), without signiﬁcant
interaction terms. Geometric mean was 17.5 ppb in a healthy female non smoker of
height 170 cm, whereby respiratory allergy corresponded to a change by factor 1.50,
smoking 0.63, infection 1.24, male gender 1.17, and each 10 cm increase (decrease) in
height to 1.11 (0.90). Factors were virtually identical when excluding asthma and using the
category allergic rhinitis instead of respiratory allergy (n ¼ 863). Within each category
formed by combinations of these different predictors, the range of residual variation was
approximately constant. We conclude that the factors inﬂuencing exhaled nitric oxide,
which we analyzed, act independently of each other. Thus, circumstances such as smokingElsevier Ltd. All rights reserved.
5160 2449; fax: +49 89 5160 3957.
d.uni-muenchen.de (H. Dressel).
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Exhaled nitric oxide: Independent effects 963and respiratory tract infection do not appear to affect the usefulness of exhaled nitric
oxide, provided that appropriate factors for adjustment are applied.
& 2008 Elsevier Ltd. All rights reserved.Table 1 Characteristics of the study population.
n 897
Female, n (%) 514 (57.3)
Age, yr 34.5713.0
Height, cm 172.078.8
Weight, kg 71.4715.7
BMI, m/kg2 24.074.3
FENO, ppb
 19.6C1.92
FEV1, %predicted 106.6713.4
FVC, %predicted 110.3713.3
FEV1/VC, %predicted 98.377.9
Respiratory allergies (rhinitis and/or
asthma), n (%)
206 (23.0)
Allergic rhinitis, n (%) 193 (21.5)
Allergic asthma, n (%) 34 (3.8)
Current smoking, n (%) 218 (24.3)
Respiratory tract infection, n (%) 190 (21.2)
Data are presented either as the number of subjects (% in
parentheses) or as mean7SD. BMI ¼ body mass index,
FENO ¼ fractional concentration of exhaled nitric oxide,
FEV1 ¼ forced expiratory volume in 1 s, FVC ¼ forced vital
capacity.
Due to the data distribution geometric mean and SD are
given, the latter being expressed as a factor indicated byC.
The geometric mean has to be multiplied with and divided by
this SD factor.Introduction
A multitude of studies have demonstrated the usefulness of
measuring the fraction of exhaled nitric oxide (FENO) in
patients with asthma,1 allergic rhinitis, or atopy,2 including
the evaluation of treatment effects.3 Besides disease and
therapy,4 there are further factors inﬂuencing FENO.
5 Some
of these, such as performing spirometry prior to FENO
measurement,6 can be easily taken into account in clinical
practice, while this is more difﬁcult for others, such as
current smoking or respiratory tract infections, which are
difﬁcult to exclude in patients visiting a physician.
Smoking leads to a decrease in FENO,
7 though values are
still higher in smokers with asthma than in those without.8
The effects of smoking have been further speciﬁed by
revealing that the logarithm of FENO showed additive
contributions from smoking history and the hours since the
last cigarette.9 FENO is also known to be elevated in upper
respiratory tract infections,10 and correspondingly in ex-
acerbations of patients with chronic obstructive pulmonary
disease (COPD)11 or in pulmonary infections of lung
transplant patients.12 Studies furthermore demonstrated
an association with height13 and gender14; the latter,
however, might be attributable to differences in height.13
In addition, age might be associated with FENO,
13 especially
in children15 and very old subjects showing elevated
values.16
While clearly establishing the inﬂuences on FENO, the
available results are not easily applicable for the evaluation
of individual values in clinical practice. Some studies were
restricted to healthy subjects with and without atopy,14,15,17
and others2,13 described the multiple effects with great
scrutiny in large populations but the complex results did not
translate into easily applicable schemes. Only one study18
based on a large random sample reported reference ranges
for combinations of factors as derived by multivariate
analysis. In addition, most studies did not include respira-
tory tract infections into the set of multiple potential
inﬂuence factors and the issue of interactions with this
factor remains unresolved. Correspondingly, a common
conclusion seems to be, e.g., that FENO is difﬁcult to
interpret in smokers or subjects suffering from respiratory
tract infections, and FENO is often not assessed in these.
Therefore, an analysis of factors affecting FENO that aims
to meet the practical need for simple, transparent, broadly-
to-apply reference values could be a step forward. On the
statistical side this involves as a major question, whether
the various factors show multiple interactions, including
different ranges of variation in different strata, or whether
they act independently of each other, with similar variation.
The latter would offer the potential to derive a reference
state with easily applicable factors for adjustment and
variability. It would thus probably facilitate a sensible use of
FENO measurements across populations. Consequently, the
aim of the present study was to quantify the single andcombined effects and interactions of factors such as
respiratory allergy, smoking, respiratory tract infection,
height, lung function, age and gender on FENO, with special
focus on the attempt to express the results in a form that
favored their application in clinical practice.Methods
Study population
Measurements were performed during pre-employment
examinations and occupational preventive medical checkups
in the Outpatient Clinic for Occupational and Environmental
Medicine of the Ludwig-Maximilians-University, Munich.
Consecutive examinations (n ¼ 1037) between April 2005
and March 2007 were examined for analysis. Subjects using
oral or inhaled corticosteroids, or showing airways diseases
other than asthma and rhinitis or with incomplete data were
excluded from the analysis. In case of repeated measure-
ments the ﬁrst one was taken. After applying these criteria
897 subjects were included (Table 1). This population
comprised 34 subjects with mild allergic asthma, having
either no or only bronchodilator therapy. Analyses were
performed either with or without these subjects.
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FENO was determined during a single exhalation using a
chemiluminescence analyzer (NOA 280TM, Sievers, Boulder,
Co, USA) according to international guidelines.5 After
inhaling ambient air subjects started to expire through a
mouthpiece against a positive pressure, aiming to achieve a
ﬂow rate of 50mL/s under visual control on a computer
screen. Ambient air levels normally showed NO levels
o15 ppb and a correlation analysis showed no relationship
between FENO and ambient air NO. Measurements were
performed at least in triplicate. The mean of three
reproducible values was taken for analysis. Acceptable
measurements had to show a clearly identiﬁable plateau
(within 10% of each other, typically o5%) and a ﬂow rate
within 10% (typically o5%) of the target rate during the
plateau measurement. The analyzer was calibrated regu-
larly using a certiﬁed calibration gas (Linde AG, Munich,
Germany).
Afterwards, inspiratory vital capacity (VC) and forced
expiratory volume in 1 s (FEV1) were determined (Master-
LabTM, Jaeger, Germany) following the established guide-
lines.19 At least three technical acceptable ﬂow-volume
maneuvres were performed and the highest values were
taken. The presence of respiratory allergies (allergic rhinitis
and/or asthma; yes/no), smoking during the last 4 weeks
(yes/no) and respiratory tract infection during the last 4
weeks (yes/no) was assessed by a physician when taking the
subjects’ history. The study was approved by the Ethical
Review Board of the LMU Munich.Table 2 Coefﬁcients of log10 FENO with 95% conﬁdence
intervals (95%CI) as obtained in 897 subjects in the ﬁnal
ANCOVA model comprising subjects with asthma.
Variable Coefﬁcient (95%CI)
Intercept 0.453 (0.061; 0.846)
Male gender 0.070 (0.028; 0.111)
Respiratory allergy 0.175 (0.136; 0.213)
Smoking 0.203 (0.240; 0.165)
Respiratory tract infection 0.092 (0.052; 0.131)
Height per 10 cm (regression
coefﬁcient) 0.0464 (0.0230; 0.0700)Data analysis
In accordance with the usual approach, values of FENO were
log10-transformed for all statistical analyses to achieve their
normal distribution. The log-transformed values were used
to derive geometric mean values and standard deviations
(SD) of FENO. Geometric SD was expressed as a dimensionless
factor with regard to the geometric mean value, and this
speciﬁc relation was indicated by the symbolC. The log10
FENO values were also used as dependent variables in
analyses of covariance (ANCOVA), which represents a
combination of standard analysis of variance (ANOVA) and
multilinear regression analysis. The linear covariates used
were age, height, weight, body mass index (BMI), FEV1 and
VC. The dichotomous variables were gender, respiratory
allergy, smoking and respiratory tract infection. The model
was computed either including or excluding subjects with
asthma (n ¼ 34), corresponding to either the category
respiratory allergy (when including asthma) or allergic
rhinitis (when excluding asthma).
The basic ANCOVA model incorporated not only the linear
superposition of all main factors but also all interactions.
Based on the p-values regarding the different predictors and
interaction terms and by eliminating the term with the
greatest p-value in a step-down fashion, a minimal model
was derived. In case of correlated covariates the validity of
the approach was checked by alternative choices of
covariates to avoid potentially misleading correlations. As
all interactions turned out to be non-signiﬁcant, the ﬁnal
minimal model provided estimates of the four remainingmain effects (categories) and one linear regression coefﬁ-
cient (see results). As it could have been possible that the
regression coefﬁcient took different values in the subgroups
formed by the categories, additional linear regression
analyses were performed within these subgroups.
The approach described resulted in a standard additive
ANCOVA model for log10 FENO. As addition of log values
corresponds to multiplication of non-log values, this led to a
multiplicative model regarding FENO. To obtain the FENO
model we retransformed all ANCOVA terms using the antilog.
Thus, the additive terms in the model for log10 FENO became
multiplicative terms in the model for FENO. These multi-
plicative terms represent the effects of different factors on
FENO relative to a reference value.
The result was also given as an explicit formula compris-
ing all factors of inﬂuence relative to the geometric mean
FENO of a reference state. To facilitate the practical
application, we additionally computed tables of FENO
stratiﬁed according to gender and height. These tables
were adjusted for the remaining (categorical) predictors,
whose effects can be taken into account by the multi-
plicative factors reported. The p-values o0.05 were
considered statistically signiﬁcant. Statistical calculations
were performed using SPSS 14.0 (SPSS Inc., Chicago, IL).Results
Table 1 shows the characteristics of the study population.
Geometric mean (CSD) FENO was 19.6C1.92 ppb in the
whole study population. Univariate analyses (t-test) showed
FENO to be lower (po0.001 each) in females (17.4C1.91 vs.
23.0C1.86 ppb), subjects without respiratory allergies
(17.8C1.78 vs. 27.3C2.16 ppb), smokers (13.5C1.98 vs.
22.1C1.81 ppb) and subjects without respiratory tract
infection (18.5C1.88 vs. 24.1C1.99 ppb) as compared to
their respective counterparts. Subjects with allergic rhinitis
and asthma showed higher values than those with allergic
rhinitis without asthma (42.1C2.2 vs. 26.4C2.1 ppb;
p ¼ 0.008).
The ﬁnal ANCOVA models did not comprise any interac-
tions, as these were statistically nonsigniﬁcant (pX0.23
each). Respiratory allergy, smoking, respiratory tract infec-
tion and gender remained as categorical factors and height
as a covariate (pp0.001 each) in the model comprising
subjects with asthma; Table 2 provides the coefﬁcients
relating the predictors to log10 FENO. The explained variance
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Figure 1 Mean and standard deviation (SD) of FENO (log scale) in the subgroups formed by different combinations of the variables
smoking, respiratory tract infection (RTI) and respiratory allergy (n ¼ 897). Panel A shows the measured data in the sample, panel B
the data adjusted to female gender and a height of 170 cm. The graph illustrates that the different variables of inﬂuence were
additive with regard to the mean (expected) value of FENO. This can be seen e.g. within the left four bars where the presence of an
RTI in non-smokers results in the same upward shift of FENO for allergic and non-allergic subjects, i.e., RTI acts homogenously and
independent from allergy. The same is true when recognizing that e.g. for smoking in panel B the pattern of the left four bars is very
similar to that of the right four bars but lowered by a certain amount which represents the effect of smoking acting homogeneously
on the groups formed by the combinations of the two variables, allergy and RTI.
Exhaled nitric oxide: Independent effects 965(R2) was 25.7% of the total variance. Figure 1A illustrates
FENO in the eight subgroups formed by the possible
combinations of allergy, smoking and infection. Virtually
the same picture, though on a lower overall level, emerged
when values were adjusted to female gender and normal-
ized to height 170 cm (Figure 1B).
To test for the homogeneity of the relation between FENO
and height as derived from ANCOVA, we performed
additional linear regression analyses within each of the
two subgroups formed by each categorical predictor. All
regression coefﬁcients regarding height were different from
zero (po0.02 each), and all of their 95% conﬁdence
intervals were overlapping. Based on these results, a single
additive model that comprised no interactions between the
categorical variables and no interaction betweeen the linear
covariate height and the categorical variables described
log10 FENO adequately. After retransformation of parameter
values from the log into the original FENO domain, the
corresponding formula for the expected value of FENO was
FENOðppbÞ ¼ 17:49 1:496
allergy
yes
 
 0:627
smoking
yes
 
 1:235
infection
yes
 
 1:174
male
yes
 
 1:113ðheightðcmÞ170Þ=10.
When the ANCOVA analysis was restricted to patients with
allergic rhinitis without asthma, the results were virtually
the same. To illustrate the application of these formulae,
Table 3 provides geometric mean values of FENO for females
over a height range from 160 to 185 cm in intervals of 5 cm,
and for males over a height range from 165 to 190 cm in the
population including subjects with allergic asthma.
As a next step, we compared variances within the
subgroups formed by the possible combinations of allergy,
smoking and infection. These variances were signiﬁcantly
different from each other (Levene test, po0.001); however,
SD values within the different subgroups (see Figure 1)differed from the adjusted pooled SD by not more than 24%
and 22%. For practical purposes we thus considered it
justiﬁed to take the pooled variance of adjusted values as
the variation within each of the subgroups. To describe the
range of variation within each of the subgroups deﬁned by
combination of the categorical predictors, the correspond-
ing expected value of FENO (see formula or Table 3) can be
multiplied either by the factor respresenting the geometric
pooled adjusted SD or by factors representing percentiles.
Following the arguments given above, these factors can be
taken as approximately the same for all subgroups. The
respective adjusted SD factor was 1.753, while the 5th and
the 95th percentile factors were 0.421 and 2.44, respec-
tively, and the 10th and 90th percentile factors 0.502 and
1.97.Discussion
The present study addressed the combined effects and
potential interactions of factors that are known to affect
the level of FENO. The factors studied covered basic
anthropometric characteristics as well as circumstances
often encountered in patients visiting an outpatient clinic.
As a result, the statistically signiﬁcant predictors which
comprised respiratory allergy or allergic rhinitis, smoking,
respiratory tract infection, gender and height were found to
have quite homogeneous effects on FENO. The homogeneity
was reﬂected in an additive model of log FENO, containing
only main factors without signs of statistical interaction.
Upon retransformation of the logarithm into the original
FENO domain, the model translated into a simple multi-
plicative scheme to adjust for various effects on FENO.
Regarding the kind of inﬂuences on FENO, our ﬁndings
were in accordance with published data. FENO is known to be
elevated in subjects with atopy without symptoms,20 or
allergic rhinitis,2 or asthma.1 The variable respiratory
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Table 3 Examples of expected geometric mean values of FENO (ppb) in females and males as derived from the formula given
in the results.
Females
Smoking     + + + +
Infection   + +   + +
Allergy  + – +  +  +
Height (cm)
160 15.7 23.5 19.4 29.0 9.9 14.7 12.2 18.2
165 16.6 24.8 20.5 30.6 10.4 15.5 12.8 19.2
170 17.5 26.2 21.6 32.3 11.0 16.4 13.5 20.2
175 18.5 27.6 22.8 34.1 11.6 17.3 14.3 21.4
180 19.5 29.1 24.0 35.9 12.2 18.2 15.1 22.5
185 20.5 30.7 25.4 37.9 12.9 19.3 15.9 23.8
Males
Smoking     + + + +
Infection   + +   + +
Allergy  +  +  +  +
Height (cm)
165 19.5 29.1 24.0 35.9 12.2 18.2 15.1 22.5
170 20.5 30.7 25.3 37.9 12.9 19.2 15.9 23.8
175 21.7 32.4 26.7 40.0 13.6 20.3 16.8 25.1
180 22.8 34.2 28.2 42.2 14.3 21.4 17.7 26.4
185 24.1 36.1 29.8 44.5 15.1 22.6 18.7 27.9
190 25.4 38.0 31.4 47.0 15.9 23.8 19.7 29.4
To estimate the variation within each of the categories, the FENO value has to be multiplied with the 5th or 10th or 90th or 95th
percentile factors (0.42, 0.50, 1.97, and 2.44, respectively).
H. Dressel et al.966allergy used by us included allergic rhinitis and/or asthma as
reported by the subjects. We did not additionally validate
the answers through objective markers of atopy or assess-
ment of bronchial hyperreactivity; thus, we cannot rule out
a bias concerning this variable. The questions we used are
standard tools to assess allergic rhinitis and asthma in large
international surveys.21 If there should have been a bias, it
possibly has favored negative answers, as subjects may have
symptoms but are not aware of their diagnosis, leading to
underestimation of the effects of atopy on FENO. However,
the factor which we found was even greater than those
reported previously by using objective markers.13,18
The number of subjects reporting asthma was low
(n ¼ 34), not allowing for further stratiﬁcation. We only
included subjects without steroid medication, i.e., presum-
ably mild asthma. These subjects accounted for 3.8% of the
study population, in accordance with the expected pre-
valence in the general population. It seemed reasonable to
keep these subjects in the analysis as lung function was
normal and FENO values were not biased by corticosteroids.
The combination of self-reported allergic rhinitis and/or
asthma into a single variable could be considered question-
able. We would like to note, however, that the statistical
model of log FENO remained essentially unchanged, when
using the category of allergic rhinitis and restricting the
analysis to subjects without asthma.
We did not document whether the allergic rhinitis was
persistent or seasonal and also did not have reliable
information whether subjects with seasonal allergies were
examined in their respective season. This might be of
interest as FENO values, which are on average lower inallergic rhinitis compared to asthma22 can reach similar
levels after allergen exposure.23 Since under the conditions
of clinical practice acute allergen exposure seems to be
difﬁcult to assess with reliability, we focused on the mere
presence of a clinically apparent respiratory tract allergy,
neglecting the exposure status. Using this approach the
multiplicative adjustment of FENO for allergy was found to
be about 1.50, being similar in all subgroups. From the
average effect size reported by Olin et al.,13 an average
factor of 1.23 across the population studied can be derived,
and in another study18 this value was 1.19. The higher factor
found in the present study might be well explained by the
fact that subjects were required to report not the presence
of elevated IgE or positive skin prick test but the occurrence
of clinical symptoms, at present or in the past. Most
importantly for practical purposes, our results proved that
a single factor of FENO with regard to respiratory allergy
could be applied independently from other inﬂuences on
FENO.
A second major inﬂuence on FENO is exerted by smoking,
which has been consistently shown to reduce FENO levels,
although the effect has not often been studied using
multivariate models. We used only the information on
current smoking, as this is primarily available in clinical
practice. Smokers with asthma have been shown to exhibit a
short-term increase of FENO after smoking, with a half-life of
about 2.4 h, that in the log domain was additive to the long-
term effect,7 while in smokers without asthma FENO was
elevated 1 and 10min after inhalation of a cigarette, with
return to the baseline within 20min.24 In our setting, the
time until measurement after the subject’s arrival was
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FENO unlikely.
The picture emerging from the literature with regard to
daily or cumulative cigarette consumption is not fully
consistent. FENO has been reported to differ between never-
and ex-smokers, after adjustment for gender, age, height,
IgE sensitization and FEV1.
25 In contrast, within a large
population-based study, also stratifying by gender and
atopy, there was no such difference.13 Moreover, in subjects
quitting smoking FENO is known to increase to about the
level measured in normal nonsmokers within 1–8 weeks of
abstinence.26,27 We considered these ﬁndings as a justiﬁca-
tion to subsume ex- and never-smokers into the same
category. Stratiﬁcation of ex-smokers according to the
time since smoking cessation and pack years would also
have stressed the limits of multivariate analysis capabilities
in our sample. Probably these factors play a role mainly in
the presence of clinically relevant COPD (GOLDX1) which
we excluded. The available data suggest that a decrease in
FENO by about factor 0.84 for each 10 pack years can occur,
but only in subjects with asthma.9 As these subjects
represented only a small proportion of our sample, we
considered the cumulative smoking history as a minor issue
regarding FENO.
While there are considerable data demonstrating the
effect of smoking on FENO, the appropriate adjustment has
been rarely studied using log NO analysis. In comprehensive
multivariate models comparing smokers with never- and
ex-smokers, the overall factor of FENO corresponding to
smoking was 0.7 in one study,13 and 0.8 for smokers
compared to non-smokers in another,18 similar to the
value of 0.63 we found. FENO is also known to be decreased
in smokers compared to non-smokers, if subjects have
asthma.8,28 Moreover, the mean values reported in a
comprehensive study13 and stratiﬁed according to atopy
allow us to derive factors for current smoking vs. non-
smoking of about 0.70 in atopic and 0.63 in nonatopic
subjects. One of the novel ﬁndings of our study was the
explicit proof of a similar effect of smoking in all subgroups
including those stratiﬁed by respiratory allergy, respiratory
tract infections and gender, as demonstrated by the absence
of interaction terms and illustrated by the parallel shift in
Figure 1. This allows the use of a single multiplicative factor
to adjust for smoking independently from other inﬂuencing
variables, which seems to be particularly useful for clinical
practice.
In our study population the presence of respiratory tract
infections during the last 4 weeks was associated with
elevated FENO values. The respective factor was 1.24, again
similar in all subgroups and without interactions. The
infections may have included a variety of locations and
viral or bacterial pathogens. Rhinovirus infection has been
shown to raise FENO,
29,30 and 1–2 days after the onset of
symptoms normal subjects with symptomatic upper respira-
tory tract infections showed increased FENO.
10 Three weeks
later FENO was back to normal. Our subjects were asked for
respiratory tract infections during the last 4 weeks, as we
wanted to keep the time window large enough to exclude
potential effects on the values used as reference. Although
the effect of infection might have been underestimated, it
was still considerable. The corresponding increase was
smaller than that indicated by another study,10 which,however, at that time used a method greatly affected by
nasal NO. Unfortunately, our ﬁndings cannot be compared
with those of the large population-based studies, as these
did not report a variable for respiratory tract infection.13,18
Our ﬁndings indicate that respiratory tract infections should
be taken into account regarding FENO and that this can be
easily done by a constant multiplicative factor.
Both gender and height turned out to be independently
associated with FENO, corresponding to a factor of 1.17 for
male vs. female gender and of 1.11 per 10 cm increase in
height. Gender has been reported as a determinant of FENO
in adults,14 while there was no association with height.
Multivariate analysis of data from a community survey
derived a 1.26 times higher FENO in males compared to
females.18 However, there are also data indicating that the
association between FENO and gender is explained by
differences in height.13,17 Remarkably, the average factor
relating FENO to height as derivable from these data was
about 1.14 and 1.09 per 10 cm increase and thus very similar
to the coefﬁcient found by us. Height was found to be the
major determinant of FENO also in healthy children, in
contrast to gender.31 Our data indicate that in adults both
gender and height are relevant for FENO and that their effect
is independent of that of other predictors.
An increase of FENO with age has been found,
13,17 in the
range of 1.09 per 10-year increase as can be derived from
these data, while other results did not indicate such a
dependence.14,18 Moreover, increases of FENO with age have
been reported in children,15 as well as elevated values in
very old subjects.16 We did not observe an association of
FENO with age in our study population. This might have been
partially due to the low average age and the small number of
older subjects. Irrespective of this, the clear-cut and robust
effect of height demonstrated that the power to identify
independent covariates in the range of subjects studied was
high.
Considering the potential practical implications of our
ﬁndings, it should be noted that there was still great
residual variation within the different strata. This is
illustrated by the ratios between standard deviations and
differences between groups (Figure 1). It is an open question
whether there are other easy-to-assess predictors that could
markedly reduce the observed residual variation, which
seems to reﬂect the multifactorial character of FENO. Other
measures related to airway inﬂammation, such as sputum
eosinophilia or bronchial hyperreactivity, are known to show
correlations with FENO,
32 which are independent from
confounders like height and gender.33 Based on the fact
that variation was similar across strata, we propose a single
set of factors for describing the variation. This greatly
simpliﬁes their use. The factors representing the 10th and
90th percentiles turned out to be about 2, and those
representing the 5th and 95th percentiles about 2.5, again
user friendly. These factors will allow location of a patient’s
FENO within the respective stratum for all practical purposes
sufﬁciently well.
There are, however, limitations to be considered. The
different strata were occupied by unequal numbers of
subjects, although this did not grossly affect our analysis.
Figure 1 indicates that shifts were close to parallel, the
largest one occurring in the group of smokers with
respiratory tract infection and respiratory allergy which
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for longitudinal follow-up in the same individuals.3 In
contrast, single measurements of absolute levels must not
be overstressed, due to the broad range of variation.
Moreover, calibration errors and gas stability are practically
relevant issues, despite the fact that commercial analyzers
seem to yield comparable readings.34 However, another
study found signiﬁcantly different FENO values when
comparing different FENO analyzers.
35 These ﬁndings have
an impact on absolute values of FENO by altering the basic
reference value assumed, but not on our result of an
independent superposition of different factors of inﬂuence
on FENO.
In conclusion, the results of the present study suggested
the use of independent multiplicative factors to adjust FENO
for the inﬂuence of the predictors respiratory allergy,
smoking, respiratory tract infection, gender and height.
Moreover, the distribution of data within the strata formed
by the predictors could be described by a single set of
multiplicative factors. Qualitatively and quantitatively, our
ﬁndings ﬁt well those of published studies involving
comprehensive, detailed analyses. In addition to these,
they offer an easily applicable scheme to adjust for
patients’ characteristics and circumstances that are com-
mon in real-life clinical practice.Conﬂict of interest statement
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